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Abstract
Mutations in the coding sequence of SOX9 cause campomelic dysplasia (CD), a disorder of 
skeletal development associated with 46,XY disorders of sex development (DSDs). 
Translocations, deletions and duplications within a ~2 Mb region upstream of SOX9 can 
recapitulate the CD-DSD phenotype fully or partially, suggesting the existence of an unusually 
large cis-regulatory control region. Pierre Robin sequence (PRS) is a craniofacial disorder that is 
frequently an endophenotype of CD and a locus for isolated PRS at ~1.2-1.5 Mb upstream of 
SOX9 has been previously reported. The craniofacial regulatory potential within this locus, and 
within the greater genomic domain surrounding SOX9, remains poorly defined. We report two 
novel deletions upstream of SOX9 in families with PRS, allowing refinement of the regions 
harbouring candidate craniofacial regulatory elements. In parallel, ChIP-Seq for p300 binding sites 
in mouse craniofacial tissue led to the identification of several novel craniofacial enhancers at the 
SOX9 locus, which were validated in transgenic reporter mice and zebrafish. Notably, some of the 
functionally validated elements fall within the PRS deletions. These studies suggest that multiple 
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non-coding elements contribute to the craniofacial regulation of SOX9 expression, and that their 
disruption results in PRS.
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Introduction
SOX9 (MIM# 608160) is an HMG-box transcription factor with multiple roles during 
embryonic development (reviewed in Pritchett et al., 2011). Conditional deletion in mice has 
demonstrated that Sox9 is essential for the development of progenitors of chondrocytic, 
neuronal, pancreatic and Sertoli lineages, amongst others. Sox9 also plays a role in the 
production of neural crest cells (NCCs) from the dorsal neural tube in several species 
(reviewed in Lee and Saint-Jeannet, 2011), and NCC-specific knockout mice fail to develop 
craniofacial cartilage (Mori-Akiyama et al., 2003). In humans, haploinsufficiency of SOX9, 
due to coding mutations, results in campomelic dysplasia (CD; MIM# 114290), a skeletal 
dysplasia often associated with disorders of sex development (DSDs). A frequent 
component of CD is Pierre Robin sequence (PRS; MIM# 261800), which involves micro- 
and/or retrognathia, glossoptosis and cleft palate. PRS in its isolated form is a relatively 
frequent craniofacial anomaly, with the initiating event thought to be defective mandibular 
outgrowth, although the underlying genetic causes are unknown in the vast majority of cases 
(Tan et al., 2013). Non-coding lesions (translocations, deletions, duplications) upstream of 
SOX9 have suggested a complex regulatory domain controlling tissue-specific expression of 
SOX9 during embryonic development. These lesions typically result in endophenotypes of 
complete CD, and approximate genotype-phenotype correlations can be made: within a 1 
Mb domain upstream of SOX9, translocation breakpoints falling close to SOX9 typically 
result in CD, while those further upstream tend to result in acampomelic campomelic 
dysplasia (ACD; MIM# 114290), a milder version of CD without limb involvement 
(reviewed in Gordon et al., 2009; Leipoldt et al., 2007). A series of large duplications 
0.78-1.99 Mb upstream were associated with brachydactyly anonychia (BA; MIM# 106995) 
(Kurth et al., 2009), while duplications, a triplication or deletions of a region 517-595 kb 
upstream lead to DSDs (Benko et al., 2011; Cox et al., 2011; Vetro et al., 2011). Finally, a 
locus for isolated PRS has been identified at ~1.2-1.5 Mb upstream of SOX9, based on the 
position of a translocation breakpoint cluster (TBC) (Benko et al., 2009; Jakobsen et al., 
2007) and deletions falling immediately proximal to this TBC (Benko et al., 2009; Fukami 
et al., 2012; Sanchez-Castro et al., 2013).
Regulatory elements that drive reporter expression in specific tissues in transgenic mice 
have been identified in the region upstream of SOX9 (Bagheri-Fam et al., 2006; Benko et al., 
2009; Mead et al., 2013; Sekido and Lovell-Badge, 2008; Wunderle et al., 1998). The 
overlap of reporter expression with endogenous Sox9 expression supports the idea that 
disruption of these elements in patients with non-coding lesions result in CD 
endophenotypes due to perturbation of SOX9 expression in a restricted range of tissues. 
Mechanistically, individual elements, or regions containing many elements, may make 
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contact with the SOX9 promoter to regulate expression, despite being separated from the 
gene by large distances in cis (Maass et al., 2012; Smyk et al., 2013; Velagaleti et al., 2005; 
Zhang et al., 2012) or in trans (Maass et al., 2012). Candidate regulatory elements at the 
SOX9 locus have typically been selected for functional studies on the basis of conservation 
between distantly related species. However, only a small fraction of the conserved non-
coding elements (CNEs) have been tested for regulatory activity. In the PRS locus ~1.2-1.5 
Mb upstream of SOX9, two enhancers capable of driving reporter gene expression in the 
embryonic mandible have been reported, consistent with their loss, and consequent 
disruption of SOX9 expression in the mandible, being causal in PRS patients with deletions 
or translocations of this region (Benko et al., 2009). Within this PRS locus there exist at 
least 14 elements conserved between human and chicken, the regulatory potential of which 
has not been tested. Also, reporter studies have demonstrated that some craniofacial 
enhancers exist much closer to SOX9 (Bagheri-Fam et al., 2006; Mead et al., 2013; Sekido 
and Lovell-Badge, 2008; Wunderle et al., 1998); restricted disruption of these elements 
could theoretically lead to craniofacial phenotypes similar to those associated with the 
lesions far upstream.
Here we screened patients with non-syndromic PRS for microdeletions at the SOX9 locus in 
order to highlight non-coding regions that may harbour novel craniofacial regulatory 
elements. We combined this with a global analysis of chromatin marks at the Sox9 locus in 
mouse embryonic craniofacial tissue. Our findings suggest that appropriate expression of 
SOX9 during craniofacial development is achieved via the action of multiple discrete 
regulatory elements.
Materials and Methods
Comparative genomic hybridisation
The PRS183 deletion was identified using a custom-designed oligonucleotide microarray 
(Agilent Technologies) consisting of 44,000 60-mer oligonucleotide probes (eArray, Agilent 
Technologies). The design included the following genomic regions (hg19): FBN2 (MIM# 
612570) (chr5:125,172,101-128,172,101), SOX9 (chr17:67,988,405-71,988,405), SATB2 
(MIM# 608148) (chr2:198,591,755-201,191,755), TBX1 (MIM# 602054) 
(chr22:19,720,000-19,820,000) and TBX22 (MIM# 300307) (chrX:78,613,344-79,963,344) 
with an average probe spacing of 260 bp. “Dye-swap” experiments were performed for each 
patient sample to reduce the variation related to labelling and hybridisation efficiencies. 
Briefly, 1 μg of genomic DNA from the patient and the control (pool of 5 samples) was 
digested with AluI and RsaI enzymes, and the digested DNA was labelled with Cyanine 3-
dUTP or Cyanine 5-dUTP in dye-swap reactions, followed by hybridization, as per the 
manufacturer's instructions (Agilent Technologies). Slides were scanned using an Axon 
GenePix 4000B scanner (Molecular Devices). Images were extracted and normalised using 
the linear-and-Lowess normalisation module implemented in the Feature Extraction 
software (Agilent Technologies). An R-script was used to correct for systematic differences 
in probe efficiencies seen on a particular array using the “self-self” microarray data (T. 
Fitzgerald, personal communication). The GC bias (or wave profile) was also corrected 
using a 500 bp window around each probe (Marioni et al., 2007). Copy number analysis was 
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carried out with DNA Analytics software (Agilent Technologies) using the aberration 
detection module (ADM)-2 algorithm (Lipson et al., 2006) with a threshold of 6 and at least 
5 consecutive probes showing a change in the copy number.
19 non-syndromic PRS patients were screened for copy number variants at the SOX9 locus 
using a NimbleGen fine-tiling custom array covering chr17:37,612,234-73,596,758 (these 
and all co-ordinates herein refer to assembly hg19), with a mean probe spacing of 37 bp 
(used for the identification of the PRS116 deletion). (Note that different custom-designed 
CGH arrays were used for screening case PRS183 versus the subsequent 19 non-syndromic 
PRS patients because each microarray was designed independently by the FitzPatrick and 
Lyonnet labs, respectively). Approval for human genetic research was obtained from the 
Comité de Protection des Personnes Ile-de-France II.
Genomic qPCR
Quantitative real-time PCR was used to assess the presence or absence of the upstream 
SOX9 deletion in family PRS183. Reactions were carried out in triplicate and consisted of 
10 ng of genomic DNA, 1 μM of each of the forward (TCTCCCAGGAGATCTTTCAATG) 
and reverse (GCAGCTGCGAGCCATTAT) primers, 5 μl of 2X TaqMan™ Universal 
Master Mix (Applied Biosystems), 0.5 μl of 20X VIC-labelled RNaseP internal control 
(Applied Biosystems), 0.1 μM of FAM-labelled Universal Probe Library (UPL) probe 59 
(Roche Diagnostics) and 0.5 μl of PCR-grade water. Amplification and real-time data 
collection was performed on an HT7900 instrument (Applied Biosystems) using the 
following conditions: 50°C for 2 minutes, 95°C for 10 minutes, followed by 40 cycles of 
95°C for 15 seconds and 60°C for 1 minute. After completion of PCR, fluorescence was 
read using the software SDS (Applied Biosystems) and the resulting Ct values were 
exported and DNA copy number determined.
Sequencing
Purification of genomic DNA from lymphocytes and Sanger sequencing were performed 
following standard protocols. Sequences of primers used for amplification and sequencing 
of the FOXC2 (MIM# 602402) coding region and the family F1 and PRS116 deletion 
breakpoints are available upon request. The FOXC2 variant identified in family F2 has been 
submitted to a relevant locus-specific database (http://www.lovd.nl/FOXC2).
ChIP-Seq, mouse transgenesis, optical projection tomography (OPT)
ChIP-Seq analysis of genomic regions immunoprecipitated by an anti-p300 antibody from 
E11.5 mouse craniofacial tissue (including nasal, maxillary, and mandibular prominences), 
generation of transient transgenic mice and OPT imaging were performed as previously 
described (Attanasio et al., 2013). Primers used for amplification of elements tested in 
transgenic reporter mice are available on request (element co-ordinates are listed in Table 1). 
Transgenic reporter data described herein will be available for viewing via the Vista 
Enhancer Browser at enhancer.lbl.gov (Visel et al., 2007) and FaceBase at 
www.facebase.org (Hochheiser et al., 2011). The E11.5 craniofacial H3K27ac ChIP-Seq 
dataset was generated using similar techniques as for that of the p300 data, and will be 
presented in greater detail elsewhere (C.A., L.A.P and A.V., unpublished data). Details 
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regarding the E13.5 palatal tissue p300 ChIP-Seq data can be obtained at the FaceBase 
website; see https://www.facebase.org/content/chip-seq-analysis-p300-bound-regions-e135-
mouse-palates.
Zebrafish transgenesis
Stable lines of transgenic zebrafish were generated and analysed following methods 
described elsewhere (Bhatia et al., in preparation and Ravi et al., 2013). Briefly, the primers 
attB4-CACTTGATGAATTTCGGCA, attB1r-CAATTACATTTCATACTGGAG and 
attB1r-CAGTTACATTTCATACTGGAG were used for amplification of wildtype and 
variant versions of HCNE-F2 from control and patient genomic DNA respectively. 
Fragments were cloned into a P4P1r entry vector before being recombined with a 
pDONR221 construct containing either a gata2 promoter-eGFP-polyA or a gata2 promoter 
mCherry-polyA cassette into a destination vector with a Gateway R4-R2 cassette flanked by 
Tol2 recombination sites. The peak 17 fragment was cloned into the gata2 promoter-eGFP-
pA reporter construct according to the same strategy using primers attB4-
GCCCTCCTGAGGAAGAGTG and attB1r-CATAATGACAGTGACCAGTG.
Immunofluorescence
Cryosections of paraformaldehyde-fixed wildtype mouse embryos were processed by 
standard techniques for Sox9 immunofluorescence. Primary antibody: rabbit polyclonal anti-
Sox9 (Chemicon, AB5535). Secondary antibody: Alexa Fluor 555 donkey anti-rabbit 
(Invitrogen, A31572).
Results
As a means to identify novel SOX9 craniofacial regulatory regions, we screened 20 patients 
with non-syndromic PRS for microdeletions at the SOX9 locus using custom-designed fine-
tiling CGH arrays. In one familial case (PRS183), the proband presented with cleft palate, 
micrognathia, crowded teeth, flat facial features and marked pectus deformity (Fig 1A). X-
rays showed hypoplastic clavicles. His brother also had cleft palate, micrognathia, flat facial 
appearance and mild pectus, while his father had a cleft soft palate and a flat midface. The 
oral abnormalities in both boys impacted on early feeding, causing failure to thrive. In the 
PRS183 proband we identified a deletion of 280 kb at 1,156 kb upstream of the SOX9 
transcription start site (maximum deletion co-ordinates, Hg19: 
chr17:68,680,882-68,965,323; minimum deletion co-ordinates: 
chr17:68,681,261-68,960,704), and genomic qPCR demonstrated segregation of the deletion 
with affected family members (Fig 1B, C). (We note that although a high-density custom 
array was used to identify this deletion, the deletion is large enough that it would likely have 
been detected using a number of commercially available microarray platforms). The 
telomeric boundary of the deletion falls within the PRS TBC, while the centromeric 
boundary falls within the F1 deletion of Benko et al. (2009) (Fig 2 and Supp. Fig S1A).
Screening of 19 additional non-syndromic PRS patients by high-density custom CGH led to 
the identification of two CNVs not listed in the Database of Genomic Variants, in the region 
surrounding SOX9. Firstly, in the female proband of a familial case of isolated PRS (her 
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sister also presented with PRS), a 6.78 kb duplication was identified within an intron of 
SLC39A11, the next coding gene telomeric to SOX9. The duplicated region is 563 kb 
downstream of the SOX9 transcription start site. However, a duplication junction-spanning 
PCR product used to genotype other family members indicated that the duplication was 
inherited from the proband's unaffected mother, and was not present in her affected sister 
(data not shown), suggesting that the duplication was not a major pathogenic factor, and the 
case was not considered further. The other novel CNV consisted of a 6 kb deletion 407 kb 
upstream of SOX9 in the proband of family PRS116 (Fig 3A). This patient presented with 
isolated PRS. PRS was also present in her mother and maternal aunt (the latter died of 
asphyxiation three days after birth), while her maternal grandfather had feeding difficulties 
in the neonatal period, without PRS (Fig 3B). The proband's mother and maternal 
grandfather also had adult-onset hearing loss and Dupuytren's contracture (MIM# 126900). 
No radiographic anomalies were detected in the proband. The mother had supernumerary 
digital folds without radiographic anomalies of the hands. The deletion was verified in the 
proband by amplification and sequencing of a breakpoint-spanning PCR product (Fig 3A; 
chr17:69,704,137-69,710,167 deleted, inclusive). A three basepair region of microhomology 
was identified at the 5’ and 3’ breakpoints (sequence TTT); microhomology of this size is a 
frequent signature of CNV breakpoints (Conrad et al., 2010; Hastings et al., 2009). Using 
the breakpoint-spanning PCR product to genotype the family, the deletion was present in the 
proband and her affected mother and grandfather, but not in her healthy father and brothers 
(Fig 3B). The deletion falls much closer to SOX9 than the previously described PRS cases 
and does not contain any previously reported regulatory elements, but harbours a single 
CNE conserved from humans to non-mammalian vertebrates (Fig 2 and Supp. Fig S1B).
The size of the deletion in the PRS family F1 was previously reported as ~75 kb, at ~1.38 
Mb upstream of SOX9 (Benko et al., 2009). As depicted in Supp. Fig S1A, the F1 and 
PRS183 deletions are partly overlapping, suggesting that important craniofacial regulatory 
elements may fall within this region of overlap. In order to more precisely define the extent 
of overlap, and the CNEs that this region contains, we amplified and sequenced a deletion-
spanning PCR product from genomic DNA of one affected individual from the F1 family. 
This analysis indicated a deletion of 84 kb (chr17:68,663,923-68,748,011 inclusive; Hg19), 
accompanied by an insertion of 9 bp (Supp. Fig S2). The region of overlap between the F1 
and PRS183 deletions (67 kb) contains four CNEs displaying conservation of at least 70% 
over 300 bp between human and each of opossum and chicken (selected at the ECR 
Browser; http://ecrbrowser.dcode.org/) (Supp. Fig S1A and Table 1). Although two 
previously reported craniofacial enhancers, HCNE-F2 and 9CE4Z, lie centromeric to the 
PRS TBC (Benko et al., 2009), neither falls within the F1-PRS183 overlap (Supp. Fig S1A). 
(Despite several attempts, we were unable to amplify a PRS183 deletion-spanning PCR 
product; therefore the precise boundaries of the PRS183 deletion were not mapped. 
However, more than 10 non-deleted CGH probes fell between HCNE-F2 and the first 
deleted probe of the PRS183 deletion interval (a region of approximately 5 kb), indicating 
that HCNE-F2 falls outside the PRS183 deletion and hence outside the F1-PRS183 overlap.) 
This suggests that other craniofacial regulatory elements may exist within the F1-PRS183 
deletion overlap.
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The HCNE-F2 element was previously investigated because it harbours a single base variant 
in several affected individuals of a PRS family (family F2 in Benko et al., 2009). HCNE-F2 
is not conserved outside placental mammals, and was the only CNE within the F1 deletion 
that was tested for regulatory activity (Benko et al., 2009). Subsequent to that report, we 
identified features suggestive of lymphoedema-distichiasis syndrome (LDS; MIM# 153400) 
in several members of the F2 family (Fig 4). Sequencing of the coding region of the major 
candidate gene for LDS, FOXC2, revealed a 10 bp deletion, leading to a frameshift and a 
premature stop (RefSeq transcript NM_005251.2:c.975_984delCGCCGGGGGC, 
p.Ala326ThrfsX8), in the proband, his brother and his father, each of whom have PRS, and 
in the paternal grandfather who does not have PRS (Fig 4). The proband and his brother 
have not yet developed lymphoedema. PRS or cleft palate has been reported in a proportion 
of LDS patients harbouring FOXC2 mutations (Bahuau et al., 2002; Brice et al., 2002; 
Erickson et al., 2001; Fang et al., 2000; Finegold et al., 2001; Tanpaiboon et al., 2010), and 
Foxc2 homozygous null mice display mandibular dysplasia and cleft palate (Iida et al., 
1997; Winnier et al., 1997). The single base change in HCNE-F2 was inherited from the 
paternal grandmother, who did not present with PRS (Benko et al., 2009); therefore the three 
members of this family with PRS are the only three with both the FOXC2 mutation and the 
HCNE-F2 variant, suggesting that both these events may have contributed to the PRS 
phenotype. Although the variant was initially not detected in a group of control patients 
(Benko et al., 2009), the same base change has recently been reported as a SNP 
(rs78542003, T>C), with a C allele frequency of 1.433% (33 counts/2302 alleles) (from 
UCSC data last updated 2012-11-09). Previous in vitro assays suggested that the variant 
sequence modified the binding of MSX1 (MIM# 142983), a transcriptional regulator with 
essential roles during craniofacial development. To support the argument that the HCNE-F2 
variant can alter enhancer activity in vivo, we performed transgenic analysis in zebrafish 
embryos, testing the ability of the wildtype and variant versions of the enhancer to drive 
mCherry or GFP reporter expression, respectively, in four independent stable lines (each 
line harbouring both transgenes).
We found that wildtype HCNE-F2 could drive expression in the developing pharyngeal 
arches and craniofacial cartilage (but not Meckel's cartilage), while this activity was 
decreased or lost for the version harbouring the variant (representative images are shown in 
Supp. Fig S3). Collectively these results suggest that the HCNE-F2 variant is likely to play a 
less important role in the pathogenesis of PRS than previously suspected, however it 
remains possible that it may contribute to the phenotype by acting as a modifying allele in 
the presence of the FOXC2 coding mutation.
We also conducted a genome-wide analysis of craniofacial cis-regulatory activity, by 
performing ChIP-Seq for p300- or acetylated H3K27 (H3K27ac)-associated genomic 
elements in E11.5 mouse craniofacial tissue and p300-associated elements in E13.5 mouse 
palatal tissue. H3K27ac and p300 chromatin marks have been used previously as predictors 
of developmental enhancers (Rada-Iglesias et al., 2011; Visel et al., 2009). We focused on 
p300 and H3K27ac binding events (peaks) within a ~3 Mb interval encompassing Sox9. 
Following conversion from mouse to human co-ordinates (where possible), we compared 
the distribution of peaks with genomic lesions associated with PRS in previous studies and 
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the present report, with the hypothesis that the peaks represent elements involved in the 
normal expression of SOX9 during early craniofacial development, and that their loss could 
contribute to the PRS phenotype. Nine E11.5 p300 peaks were identified in the 1.9 Mb 
interval between KCNJ2 (MIM# 600681) and SOX9, and one fell within a 1 Mb region 
downstream of SOX9 (Fig 2). Apart from peak23, which falls on a portion of the SOX9 
proximal promoter, all eight other peaks in the KCNJ2-SOX9 interval overlapped a CNE 
with conservation between human and chicken (according to the Multiz alignment track in 
the UCSC browser), supporting the functional relevance of these peaks.
Importantly, five of these eight peaks (peaks 15-19) were clustered in a domain of 115 kb, 
proximal to the PRS TBC (Fig 2 and Supp. Fig S1A). Peak22 falls within the 6 kb deletion 
identified in PRS116 (Supp. Fig S1B); this is particularly striking considering that it is the 
only p300 peak within a 0.9 Mb interval upstream of the SOX9 proximal promoter (Fig 2). 
Two peaks from the E11.5 craniofacial H3K27ac and three from the E13.5 palatal p300 
ChIP-Seq studies fell in the KCNJ2-SOX9 interval (Fig 2, Supp. Fig S1A and S1B); several 
of these were also either within or adjacent to regions deleted in PRS patients.
For each of the 10 E11.5 p300 peaks, in vivo reporter activity was tested in transient 
transgenic mouse assays at E11.5, using constructs harbouring a given peak region upstream 
of lacZ (genomic co-ordinates of the regions used and a summary of in vivo craniofacial 
reporter activity are listed in Table 1). Two peaks demonstrated lacZ expression in 
mandibular mesenchyme (peaks 16 and 22; Fig 5A and Supp. Fig S4). Peak 16 drove 
expression in the proximal first arch in 4/8 embryos (Fig 5A, upper row), and peak 22 drove 
relatively weak but reproducible expression in a specific region of the mandible (5/10 
embryos; Fig 5A, lower row). Examination of OPT slices from peak 16- and peak 22-lacZ 
embryos indicated an overlap of lacZ expression with a portion of the endogenous Sox9 
protein expression domain in the mandible (Supp. Fig S4 and see Supp. Movies S1 and S2). 
Peak 23 drove reporter expression in the lower lip in 5/13 embryos and peak 24 drove 
expression in the lateral nasal prominence in 3/9 embryos. Peak 22-lacZ also displayed 
strong relative staining in distal limb bud mesenchyme (9/10 embryos; Fig 5A, lower row 
and Supp. Fig S4E). Peak 24 drove expression in an anterior domain of the limb bud in 6/9 
embryos and peak 15-lacZ showed staining in a specific region of the limb bud in 6/11 
embryos (data not shown).
The only E11.5 p300 peak falling within the minimal region of overlap between the F1 and 
PRS183 deletions is peak 17. This peak covers one of the four human-opossum-chicken 
CNEs in this minimal region of overlap. However, the peak 17 region displayed no 
reproducible lacZ reporter activity in transient transgenic mice at E11.5. Given the potential 
importance of this element, we tested its activity in a different model. We generated four 
independent lines of zebrafish stably expressing a peak 17-GFP reporter gene. We observed 
consistent expression of GFP in the region surrounding the oral cavity at 48 hpf and in first 
branchial arch-derived cartilages, including Meckel's, at 96 hpf (Fig 5B), supporting the idea 
that peak 17 functions as a craniofacial regulatory element.
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Discussion
In this report we have identified two novel deletions upstream of SOX9 in PRS patients, one 
of which (in family PRS183) partly overlaps a previously described deletion associated with 
isolated PRS, and the other (in family PRS116) falling in a region much closer to SOX9, not 
previously associated with PRS. These deletions contain or fall in close proximity to novel 
candidate craniofacial enhancers of SOX9, identified here by ChIP-Seq and validated in 
transgenic reporter assays. For each deletion, PRS was associated with other phenotypes. In 
the PRS183 family, other features included pectus deformity and flat midface (we note 
however that several features in this family displayed variable expression, with the two 
deletion-positive siblings more severely affected than their father). Although thorax 
abnormalities are common in CD, pectus deformities are not frequently reported. However, 
pectus was described in several members of a family affected with ACD (Stalker and Zori, 
1997) and harbouring a translocation breakpoint 932 kb upstream of SOX9 (Hill-Harfe et al., 
2005). The 280 kb deletion in family PRS183 falls 224 kb further proximal to this 
breakpoint, suggesting that both cases involve the disruption of regulatory elements that 
direct appropriate expression of SOX9 during thoracic skeletal development. In addition to 
family PRS183, a flattened face was mentioned in two PRS cases harbouring balanced 
translocations within the PRS TBC (Benko et al., 2009; Jakobsen et al., 2007; Vintiner et al., 
1991). A flat face being a typical feature of CD, non-mandibular craniofacial enhancers of 
SOX9 may also exist proximal to the PRS TBC. A 3 Mb deletion upstream of SOX9 was 
recently reported in a patient with PRS, scapula hypoplasia and clubfeet (Fukami et al., 
2012); in this case the telomeric breakpoint boundary also fell within the PRS TBC (see Fig 
2). It has been reported that a ~2.4 Mb region centred on Sox9 undergoes chromatin 
decompaction in the embryonic mouse mandible (Benko et al., 2009) and that SOX9 co-
localises with a region 1.1 Mb upstream in human interphase nuclei (Velagaleti et al., 2005). 
In the Odd Sex mouse mutant, a transgene insertion influences expression from almost 1 Mb 
upstream of Sox9 (Qin et al., 2004). Recently it has been demonstrated by chromatin 
conformation capture that an element 1 Mb upstream loops to the SOX9 promoter in a 
prostate cancer cell line (Zhang et al., 2012), while chromosome conformation capture-on-
chip analysis identified interactions between the SOX9 promoter and regions ~1.13 Mb and 
~967 kb upstream in Sertoli cells and lymphoblasts (Smyk et al., 2013). The above data 
support the idea that SOX9 can be regulated by a region further than 1 Mb upstream, but that 
this region is not solely involved in mandibular SOX9 expression. In family PRS116, two 
individuals harbouring the deletion had Dupuytren's contracture, a fibrotic connective tissue 
disorder that to our knowledge has not previously been described in the context of SOX9-
related disease. The relevance of this phenotype to the deletion remains unclear, however it 
is worth noting that SOX9 has been implicated in various fibrotic pathologies, where it may 
regulate extracellular matrix deposition (Pritchett et al., 2011). The same two PRS116 
individuals also had late-onset deafness, which is intriguing given the role of Sox9 in mice 
in both ossicular and otic vesicle development (Barrionuevo et al., 2008; Mori-Akiyama et 
al., 2003). Further analysis of peak 22-lacZ transgenic mice at multiple stages of 
development will be required to determine whether this element can drive expression in the 
ear.
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Our ChIP-Seq analysis of regions binding p300 in the KCNJ2-SOX9 interval led to the 
identification of several novel candidate enhancers of SOX9 expression. Transgenic analysis 
in mice and zebrafish demonstrated that peaks 16, 17 and 22 can drive reporter expression 
within the developing mandible, consistent with their loss playing a role in the pathogenesis 
of PRS in patients harbouring deletions of these elements. The PRS183 deletion reported 
here does not include the previously identified craniofacial enhancer HCNE-F2 (Benko et 
al., 2009), while the family F1 deletion (Benko et al., 2009) did not include the 9CE4Z 
enhancer. Therefore, the region of overlap between the PRS183 and F1 deletions (67 kb) 
may harbour other craniofacial SOX9 enhancers – indeed, the region contains four CNEs 
conserved from human to chicken. Notably, peak 17, which displayed craniofacial 
regulatory activity in zebrafish, falls on one of these four CNEs. Although peak 22 drove 
reproducible but relatively weak expression in the E11.5 mandible, it was strongly active in 
the distal limb bud at this stage – no previously reported SOX9 enhancer shows this degree 
of specificity within the developing limb, and it will be of interest to explore the expression 
pattern of peak 22-lacZ (along with the other limb bud-active peaks identified here; peaks 15 
and 24) at later stages of chondrogenic development. No single enhancer thus far identified 
at the SOX9 locus drives expression specifically in all chondrogenic tissue. It is possible that 
SOX9 expression in developing cartilage is achieved by the action of many regulatory 
elements, each providing maximal activity in small subdomains. Interestingly, of the two 
H3K27ac craniofacial peaks within the 1.9 Mb KCNJ2-SOX9 interval, one falls 8 kb away 
from p300 peak 22, which displayed in vivo reporter activity and falls within the PRS116 
deletion. (Note the only other H3K27ac peak falls on the SOX9 proximal promoter). Further 
upstream, p300 craniofacial peaks 15-19, p300 palate peak 1, HCNE-F2 and 9CE4Z all fall 
within a 210 kb interval proximal to the PRS TBC; note that none of these eight elements 
are overlapping, suggesting that many individual inputs may contribute to the craniofacial 
regulatory activity of the region. In addition, previous studies showed craniofacial regulatory 
activity closer to SOX9 (Bagheri-Fam et al., 2006; Mead et al., 2013; Sekido and Lovell-
Badge, 2008; Wunderle et al., 1998), and the peak 22 craniofacial enhancer identified here 
in the PRS116 deletion falls at 408 kb upstream. A major question is how these dispersed 
activities are coordinated with respect to each other and to enhancers for other cell types.
In conclusion, we have identified novel PRS-associated deletions upstream of SOX9, and we 
have utilised p300 ChIP-Seq and in vivo reporter assays to define novel craniofacial 
regulatory elements falling within these or previously reported deletions. Our data are 
consistent with the hypothesis that these elements are required for appropriate expression of 
SOX9 during craniofacial development, and that their loss contributes to the PRS phenotype.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig 1. 
A, the family PRS183 proband (panels i, left and ii) and his affected brother (panels i, right 
and iii). B, a 280 kb deletion 1,156 kb upstream of SOX9 was identified by custom high-
density 44K CGH array in the proband of family PRS183. C, the deletion was shared by his 
brother who had a similar phenotype (PRS and pectus deformity), and by his father with 
mild features of PRS, as determined by qPCR using genomic DNA from family members. 
The vertical axis of the graph represents genomic copy number relative to control. Bars of 
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the graph correspond to respective family members in the tree directly above. Error bars are 
standard error of the mean copy number.
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Fig 2. 
UCSC screenshot depicting the distribution of genomic lesions between SOX9 and KCNJ2, 
relative to positions of ChIP-Seq peaks converted from mouse coordinates. A 2.3 Mb 
interval on chr17q24.3 is shown (co-ordinates are from Hg19). Centromeric (CEN) and 
telomeric (TEL) ends are indicated. The SOX9 regulatory lesions track depicts deletions 
(del) reported in Fukami et al. (2012), Benko et al. (2009) and the present study; minimal 
critical regions (min crit reg) for brachydactyly anonychia duplications from Kurth et al. 
(2009) and for DSD duplications and deletions (see text); and PRS, distal and proximal 
translocation breakpoint clusters (TBCs) (see Gordon et al. (2009)). Whether deletion 
breakpoints are precisely (prec) or approximately (approx) mapped is indicated. HCNE-F2 
and 9CE4Z from Benko et al. (2009) and E3 from Bagheri-Fam et al. (2006) are three 
previously described craniofacial enhancers. ChIP-Seq peak tracks: regions from the mouse 
genome corresponding to p300 or H3K27ac binding events were converted, where possible, 
to human coordinates. A peak name followed by # indicates that the peak region overlaps a 
CNE conserved between human and chicken in the UCSC Multiz alignment. The dashed 
boxes are magnified in Supp. Figures S1A and S1B.
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Fig 3. 
A, a 6 kb deletion 407 kb upstream of SOX9 was identified by custom high-density CGH 
array in the proband of family PRS116. Black arrowheads indicate the approximate position 
of primers used to amplify a breakpoint-spanning PCR product. White arrowheads indicate 
the position of primers used as a control for multiplex PCR in B. The electropherogram 
displays the breakpoint-spanning sequence. Uppercase sequence, outside the deletion; 
lowercase sequence, within the deletion. A three basepair region of microhomology at the 
breakpoint is underlined. B, segregation of the 6 kb deletion in family PRS116. Genotyping 
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for the breakpoint-spanning PCR product (black arrowhead) indicates that the deletion 
segregates with affected family members. A white arrowhead indicates an internal PCR 
control for DNA quality.
Gordon et al. Page 18
Hum Mutat. Author manuscript; available in PMC 2015 August 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Fig 4. 
Identification of a FOXC2 deletion in family F2 from Benko et al. (2009). The 10 bp 
deletion induces a frameshift and a premature stop codon. rs78542003 is a SNP occurring in 
a CNE 1,441 kb upstream of SOX9 (HCNE-F2); the variant was previously reported to 
segregate with PRS in family F2 (Benko et al. (2009)). The proband is indicated with an 
arrow. A question mark indicates that it is currently unknown whether the patient has 
distichiasis.
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Fig 5. 
p300 ChIP-Seq peak regions assayed for enhancer activity in transgenic animals. A, E11.5 
transient transgenic mice harbouring reporter genes consisting of peak regions 16 (upper 
row) or 22 (lower row) upstream of lacZ. Arrows indicate mandibular expression. B, 
representative fluorescent confocal images of zebrafish embryos at 48 and 96 hpf expressing 
a stably integrated peak 17-GFP transgene. lat, lateral view; ven, ventral view; pa, 
pharyngeal arches; oc, oral cavity; Mc, Meckels's cartilage; pq, palatoquadrate.
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Table 1
Genomic co-ordinates of candidate cis-regulatory elements and reporter activity in transgenic mice
cis-regulatory elementa Co-ordinates (hg19)b Co-ordinates of regions used for 
mouse transgenic assay constructs 
(mm9)
Vista 
Enhancer 
Browser IDc
Craniofacial 
enhancer activity in 
vivo at E11.5 
(number embryos 
with activity/total 
embryos)
E11.5 p300 peak 15 chr17:68,657,930-68,658,587 chr11:111,424,415-111,425,316 mm627 no activity
E11.5 p300 peak 16 chr17:68,670,660-68,671,244 chr11:111,429,837-111,430,753 mm628 positive (4/8)d
E11.5 p300 peak 17 chr17:68,734,773-68,735,865 chr11:111,488,426-111,489,423 mm629 no activity
E11.5 p300 peak 18 chr17:68,757,543-68,758,311 chr11:111,508,642-111,510,310 mm630 no activity
E11.5 p300 peak 19 chr17:68,772,358-68,773,236 chr11:111,527,366-111,528,791 mm631 no activity
E11.5 p300 peak 20 chr17:68,930,291-68,930,938 chr11:111,642,336-111,643,268 mm632 no activity
E11.5 p300 peak 21 chr17:69,177,260-69,178,008 chr11:111,822,417-111,824,278 mm633 no activity
E11.5 p300 peak 22 chr17:69,705,542-69,709,331 chr11:112,273,180-112,274,981 mm634 positive (5/10)d
E11.5 p300 peak 23 chr17:70,115,368-70,115,821 chr11:112,641,566-112,642,353 mm635 positive (5/13)e
E11.5 p300 peak 24 chr17:70,371,357-70,373,428 chr11:112,874,476-112,876,828 mm636 positive (3/9)f
E11.5 H3K27ac peak 4 chr17:69,696,698-69,697,764 -
E11.5 H3K27ac peak 5 chr17:70,116,597-70,119,020 -
E13.5 palate p300 peak 1 chr17:68,657,258-68,657,319 -
E13.5 palate p300 peak 3 chr17:68,976,805-68,976,929 -
E13.5 palate p300 peak 4 chr17:69,972,382-69,972,452 -
hoc CNE-A chr17:68,698,451-68,699,247 -
hoc CNE-B chr17:68,731,019-68,731,632 -
hoc CNE-C chr17:68,735,308-68,735,624 -
hoc CNE-D chr17:68,747,112-68,747,577 -
a
craniofacial (or palate, as indicated) ChIP-Seq peaks and/or conserved elements. In the latter case, elements are labelled hoc CNE-A to -D. hoc 
indicates human-opossum-chicken CNEs in the F1-PRS183 deletion overlap region. Note that hoc CNE-C falls within E11.5 p300 peak 17.
b
theLiftOver tool at the UCSC genome browser was used for conversion of ChIP-Seq peak co-ordinates from mm9 to hg19.
c
element identity available for viewing via the Vista Enhancer Browser at enhancer.lbl.gov.
d
reporter expression in the mandible.
e
reporter expression in the lower lip.
f
reporter expression in the lateral nasal prominence.
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